Similar articles

• Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

  Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Sulkowski MS, et al. Hepatology. 2002 Jan;35(1):182-9. doi: 10.1053/jhep.2002.30319. Hepatology. 2002. PMID: 11786975
• Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

  Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, Rebeiro P, George AL, Kim RB, Haines JL, Sterling TR. Ritchie MD, et al. Clin Infect Dis. 2006 Sep 15;43(6):779-82. doi: 10.1086/507101. Epub 2006 Aug 15. Clin Infect Dis. 2006. PMID: 16912956
• [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].

  van Leth F, Lange JM. van Leth F, et al. Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22. Ned Tijdschr Geneeskd. 2006. PMID: 16924943 Review. Dutch.
• Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.

  Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Ena J, et al. Int J STD AIDS. 2003 Nov;14(11):776-81. doi: 10.1258/09564620360719840. Int J STD AIDS. 2003. PMID: 14624743
• Non-nucleoside reverse transcriptase inhibitors--an overview.

  Bell C, Matthews GV, Nelson MR. Bell C, et al. Int J STD AIDS. 2003 Feb;14(2):71-7. doi: 10.1258/095646203321156827. Int J STD AIDS. 2003. PMID: 12662384 Review. No abstract available.